| Literature DB >> 30630480 |
Sadie Cook1, Emily Vettese1, Dilip Soman2, Shannon Hyslop1, Susan Kuczynski3, Brenda Spiegler4, Hailey Davis1, Nathan Duong1, Stacee Ou Wai5, Robert Golabek5, Patryk Golabek5, Adam Antoszek-Rallo6, Tal Schechter7, L Lee Dupuis8, Lillian Sung9.
Abstract
BACKGROUND: We developed Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK), a web-based application designed to facilitate symptom screening by children receiving cancer treatments and access to supportive care clinical practice guidelines primarily by healthcare providers. The objective was to describe the initial development and evaluation of SPARK from the perspective of children. IMPLEMENTATION: Development and evaluation occurred in three phases: (1) low fidelity focused on functionality, (2) design focused on "look and feel" and (3) high fidelity confirmed functionality and design. Cognitive interviews were conducted with children receiving cancer treatments 8-18 years of age. Evaluation occurred after every five interviews and changes were guided by a Review Panel. Quantitative evaluation included SPARK ease of use and understandability of SPARK reports.Entities:
Keywords: Oncology; Pediatric cancer; Self-report; Supportive care; Symptom screening; Website development
Mesh:
Year: 2019 PMID: 30630480 PMCID: PMC6327501 DOI: 10.1186/s12911-018-0715-6
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1Symptom Screening in Pediatrics Tool (SSPedi)
Fig. 2SPARK Landing Page
Fig. 3General Flow of the Participant Interview
Fig. 4Patient Icons Shown in the Low-Fidelity Phase
Fig. 5High-Fidelity Phase Version of Single SSPedi Administration Report
Fig. 6Flow Diagram of Patient Identification and Participation by Phase
Demographic Information of the Participants by Phase of Development
| Low Fidelity | Design Phase | High Fidelity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SSPedi Report Design | Overall Design | Coding Sprints | Finalization | |||||||
| Cohort 1 ( | Cohort 2 ( | Cohort 3 ( | Cohort 4 ( | Cohort 5 ( | Cohort 6 ( | Cohort 7 ( | Cohort 8 ( | Cohort 9 ( | Cohort 10 ( | |
| Participant Age in Years | ||||||||||
| 8–10 | 0 | 4 | 2 | 3 | 1 | 3 | 2 | 2 | 3 | 2 |
| 11–14 | 8 | 3 | 3 | 6 | 2 | 5 | 1 | 6 | 4 | 5 |
| 15–18 | 2 | 3 | 5 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| Participant Male | 5 | 6 | 6 | 6 | 4 | 7 | 3 | 8 | 5 | 4 |
| Inpatient | 10 | 9 | 9 | 5 | 2 | 6 | 3 | 6 | 6 | 5 |
| Reason for Visit | ||||||||||
| Chemotherapy | 8 | 9 | 6 | 9 | 4 | 7 | 4 | 9 | 6 | 8 |
| Other | 2 | 1 | 4 | 1 | 1 | 3 | 1 | 1 | 4 | 2 |
| Cancer Diagnosis | ||||||||||
| Leukemia or lymphoma | 6 | 9 | 7 | 7 | 3 | 8 | 2 | 4 | 8 | 1 |
| Solid tumor | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 8 |
| Brain tumor | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Number Mostly or Completely Correct During Low and High-Fidelity (Finalization) Phases of SPARK Development by Taska
| Task | Low Fidelity | High Fidelity Finalization | ||
|---|---|---|---|---|
| Cohort 1 ( | Cohort 2 ( | Cohort 3 ( | Cohort 10 ( | |
| Ability to Perform Specific Functions | ||||
| Completing SSPedi | NA | 9 (90%) | 10 (100%) | 10 (100%) |
| Seeing current or previous SSPedi scores | NA | 10 (100%) | 10 (100%) | 10 (100%) |
| Landing Page | ||||
| Overall | 8 (80%) | 9 (90%) | 10 (100%) | 10 (100%) |
| Child icon | 10 (100%) | 10 (100%) | 10 (100%) | 10 (100%) |
| Family member icon | 10 (100%) | 10 (100%) | 10 (100%) | 10 (100%) |
| Healthcare provider icon | 10 (100%) | 10 (100%) | 10 (100%) | 10 (100%) |
| What are SPARK and SSPedi | 9 (90%) | 9 (90%) | 10 (100%) | 10 (100%) |
| Do SSPedi Now! | 10 (100%) | 10 (100%) | 9 (90%) | 10 (100%) |
| How Will SSPedi Help Me? | 9 (90%) | 8 (80%) | 8 (80%) | 10 (100%) |
| My SSPedi Scores | ||||
| Single SSPedi administration report | 10 (100%) | 10 (100%) | 10 (100%) | 10 (100%) |
| Navigating to report of a specific symptom over time | 10 (100%) | 9 (90%) | 10 (100%) | 10 (100%) |
| Interpreting specific symptom improving over time | 9 (90%) | 9 (90%) | 10 (100%) | 10 (100%) |
| Interpreting specific symptom worsening over time | 9 (90%) | 9 (90%) | 9 (90%) | 10 (100%) |
NA - not evaluated in Cohort 1 as need to test was first identified at the first Review Panel meeting
aAs assessed by a two interviewers rated on a 4-point Likert scale ranging from completely incorrect to completely correct